Literature DB >> 22580563

Cost effectiveness of the National HIV/AIDS Strategy goal of increasing linkage to care for HIV-infected persons.

Chaitra Gopalappa1, Paul G Farnham, Angela B Hutchinson, Stephanie L Sansom.   

Abstract

BACKGROUND: One of the goals of the National HIV/AIDS Strategy (NHAS) is to increase the proportion of HIV-infected individuals linked to care within 3 months of diagnosis (early linkage) from 65% to 85%. Earlier access to care, and eventually, to treatment, increases life expectancy and quality of life for HIV-infected persons. However, longer treatment is also associated with higher costs, especially for antiretroviral drugs. We evaluated the cost effectiveness of achieving the NHAS goal and estimated the maximum cost that HIV programs could spend on linkage to care and remain cost effective.
METHODS: We used the Progression and Transmission of HIV/AIDS model to estimate the effects on life measures and costs associated with increasing early linkage to care from 65% to 85%. We estimated an incremental cost-effectiveness ratio as the additional cost required to reach the target divided by the quality-adjusted life years (QALYs) gained and assumed that programs costing $100,000 or less per QALY gained are cost effective.
RESULTS: Achieving the NHAS linkage-to-care goal increased life expectancy by 0.4 years and delayed the onset of AIDS by 1.2 years on average for every HIV-diagnosed person. Increasing early linkage to care cost an extra $62,200 per QALY gained, considering only benefits to index persons. The maximum that could be cost effectively spent on early linkage-to-care interventions was approximately $5100 per HIV-diagnosed person.
CONCLUSIONS: Considerable investment can be cost effectively made to achieve the NHAS goal on early linkage to care.

Entities:  

Mesh:

Year:  2012        PMID: 22580563     DOI: 10.1097/QAI.0b013e31825bd862

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  17 in total

1.  Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.

Authors:  Rochelle P Walensky; Paul E Sax; Yoriko M Nakamura; Milton C Weinstein; Pamela P Pei; Kenneth A Freedberg; A David Paltiel; Bruce R Schackman
Journal:  Ann Intern Med       Date:  2013-01-15       Impact factor: 25.391

Review 2.  Cost-effectiveness analysis along the continuum of HIV care: how can we optimize the effect of HIV treatment as prevention programs?

Authors:  B Nosyk; E Krebs; O Eyawo; J E Min; R Barrios; J S G Montaner
Journal:  Curr HIV/AIDS Rep       Date:  2014-12       Impact factor: 5.071

3.  Cost-Utility of Access to Care, a National HIV Linkage, Re-engagement and Retention in Care Program.

Authors:  Catherine Maulsby; Kriti M Jain; Brian W Weir; Blessing Enobun; Melissa Werner; Morey Riordan; David R Holtgrave
Journal:  AIDS Behav       Date:  2018-11

4.  The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial.

Authors:  Bruce R Schackman; Lisa R Metsch; Grant N Colfax; Jared A Leff; Angela Wong; Callie A Scott; Daniel J Feaster; Lauren Gooden; Tim Matheson; Louise F Haynes; A David Paltiel; Rochelle P Walensky
Journal:  Drug Alcohol Depend       Date:  2012-09-09       Impact factor: 4.492

5.  The lifetime medical cost savings from preventing HIV in the United States.

Authors:  Bruce R Schackman; John A Fleishman; Amanda E Su; Bethany K Berkowitz; Richard D Moore; Rochelle P Walensky; Jessica E Becker; Cindy Voss; A David Paltiel; Milton C Weinstein; Kenneth A Freedberg; Kelly A Gebo; Elena Losina
Journal:  Med Care       Date:  2015-04       Impact factor: 2.983

6.  Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US.

Authors:  Pamela P Pei; Milton C Weinstein; X Cynthia Li; Michael D Hughes; A David Paltiel; Taige Hou; Robert A Parker; Melanie R Gaynes; Paul E Sax; Kenneth A Freedberg; Bruce R Schackman; Rochelle P Walensky
Journal:  HIV Clin Trials       Date:  2015-12-11

7.  Implementing Generalized Additive Models to Estimate the Expected Value of Sample Information in a Microsimulation Model: Results of Three Case Studies.

Authors:  Dustin J Rabideau; Pamela P Pei; Rochelle P Walensky; Amy Zheng; Robert A Parker
Journal:  Med Decis Making       Date:  2017-11-09       Impact factor: 2.583

8.  Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.

Authors:  Rochelle P Walensky; Tim Horn; Nicole C McCann; Kenneth A Freedberg; A David Paltiel
Journal:  Ann Intern Med       Date:  2020-03-10       Impact factor: 25.391

9.  The Epidemiologic and Economic Impact of Improving HIV Testing, Linkage, and Retention in Care in the United States.

Authors:  Maunank Shah; Kathryn Risher; Stephen A Berry; David W Dowdy
Journal:  Clin Infect Dis       Date:  2015-09-11       Impact factor: 9.079

10.  Effect of the US National HIV/AIDS Strategy targets for improved HIV care engagement: a modelling study.

Authors:  Maunank Shah; Allison Perry; Kathryn Risher; Sunaina Kapoor; Jeremy Grey; Akshay Sharma; Eli S Rosenberg; Carlos Del Rio; Patrick Sullivan; David W Dowdy
Journal:  Lancet HIV       Date:  2016-02-08       Impact factor: 12.767

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.